(0.05%) 5 471.77 points
(0.09%) 39 146 points
(0.34%) 17 778 points
(-0.10%) $80.75
(-3.66%) $2.66
(-0.76%) $2 313.10
(0.28%) $28.95
(3.59%) $1 021.80
(0.27%) $0.936
(0.68%) $10.68
(0.46%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration...
Stats | |
---|---|
今日成交量 | 422 931 |
平均成交量 | 2.12M |
市值 | 478.32M |
EPS | $-0.0209 ( Q1 | 2024-05-07 ) |
下一个收益日期 | ( $-0.0400 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.77 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00600 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-16 | Duarte Ira | Buy | 12 500 | Common Stock |
2024-06-16 | Duarte Ira | Sell | 12 500 | Restricted Stock Units |
2024-06-06 | Forbes William P | Buy | 12 500 | Common Stock |
2024-06-06 | Forbes William P | Sell | 12 500 | Restricted Stock Units |
2024-04-19 | Duarte Ira | Buy | 3 874 | Common Stock |
INSIDER POWER |
---|
66.25 |
Last 98 transactions |
Buy: 14 970 322 | Sell: 3 266 807 |
音量 相关性
Heron Therapeutics Inc 相关性 - 货币/商品
Heron Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $127.04M |
毛利润: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2023 |
营收: | $127.04M |
毛利润: | $61.94M (48.75 %) |
EPS: | $-0.800 |
FY | 2022 |
营收: | $107.67M |
毛利润: | $52.80M (49.04 %) |
EPS: | $-1.240 |
FY | 2021 |
营收: | $87.18M |
毛利润: | $41.16M (47.21 %) |
EPS: | $-2.24 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。